Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. UTHR
stocks logo

UTHR

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
802.34M
+12.23%
--
--
834.73M
+11.46%
--
--
815.25M
+10.78%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for United Therapeutics Corporation (UTHR) for FY2025, with the revenue forecasts being adjusted by 2.08% over the past three months. During the same period, the stock price has changed by -11.17%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.08%
In Past 3 Month
Stock Price
Go Down
down Image
-11.17%
In Past 3 Month
10 Analyst Rating
up Image0
Wall Street analysts forecast UTHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UTHR is 370.44 USD with a low forecast of 314.00 USD and a high forecast of 432.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
3 Hold
0 Sell
Moderate Buy
up Image0
Current: 286.880
sliders
Low
314.00
Averages
370.44
High
432.00
up Image0
Current: 286.880
sliders
Low
314.00
Averages
370.44
High
432.00
Cantor Fitzgerald
NULL -> Overweight
initiated
$405
2025-06-02
Reason
Cantor Fitzgerald
Price Target
$405
2025-06-02
initiated
NULL -> Overweight
Reason
Cantor Fitzgerald initiated coverage of United Therapeutics with an Overweight rating and $405 price target.
BofA
Buy
maintain
$22 -> $25
2025-05-26
Reason
BofA
Price Target
$22 -> $25
2025-05-26
maintain
Buy
Reason
BofA raised the firm's price target on Liquidia (LQDA) to $25 from $22 and keeps a Buy rating on the shares. The company's Yutrepia was approved as a 505b2 alternative to United Therapeutics' (UTHR) Tyvaso, the analyst tells investors in a research note. The firm says the Yutrepia label is highly similar Tyvaso, given the 505b2 nature of the regulatory program. BofA finds Liquidia shares undervalued relative to the peak sales opportunity.
Wells Fargo
Overweight -> Equal Weight
downgrade
$395 -> $314
2025-04-25
Reason
Wells Fargo
Price Target
$395 -> $314
2025-04-25
downgrade
Overweight -> Equal Weight
Reason
Wells Fargo downgraded United Therapeutics to Equal Weight from Overweight with a price target of $314, down from $395.
Wells Fargo
Tiago Fauth
Overweight -> Equal Weight
downgrade
$395 -> $314
2025-04-25
Reason
Wells Fargo
Tiago Fauth
Price Target
$395 -> $314
2025-04-25
downgrade
Overweight -> Equal Weight
Reason
Wells Fargo analyst Tiago Fauth downgraded United Therapeutics to Equal Weight from Overweight with a price target of $314, down from $395. The firm's analysis into the fundamental drivers of efficacy in the INCREASE study gives it conviction that it was driven by factors that will be difficult to replicate in TETON. While the stock may work without idiopathic pulmonary fibrosis, Wells moves to the sidelines into the data, the analyst tells investors in a research note. It believes IPF is becoming a pivotal part of the United Therapeutics story. If IPF fails, the company will face investor scrutiny on upcoming competition, capital allocation, and the pipeline, contends Wells.
B of A Securities
Greg Harrison
Sell
to
Hold
Upgrades
$314
2025-04-21
Reason
B of A Securities
Greg Harrison
Price Target
$314
2025-04-21
Upgrades
Sell
to
Hold
Reason
JP Morgan
Jessica Fye
Buy
Maintains
$357 → $355
2025-04-21
Reason
JP Morgan
Jessica Fye
Price Target
$357 → $355
2025-04-21
Maintains
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for United Therapeutics Corp (UTHR.O) is 10.00, compared to its 5-year average forward P/E of 11.98. For a more detailed relative valuation and DCF analysis to assess United Therapeutics Corp 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
11.98
Current PE
10.00
Overvalued PE
13.80
Undervalued PE
10.16

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
6.44
Current EV/EBITDA
5.97
Overvalued EV/EBITDA
7.80
Undervalued EV/EBITDA
5.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
4.63
Current PS
4.54
Overvalued PS
5.23
Undervalued PS
4.02

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

UTHR News & Events

Events Timeline

(ET)
2025-06-10
08:13:41
United Therapeutics falls after Insmed's TPIP meets endpoints in study
select
2025-06-02 (ET)
2025-06-02
06:39:29
Liquidia schedules first commercial shipment of YUTREPIA
select
2025-05-27 (ET)
2025-05-27
15:46:22
Liquidia price target raised to $37 from $29 at BTIG
select
Sign Up For More Events
Sign Up For More Events

News

Preview
3.0
06-17NASDAQ.COM
Is Insmed Stock Overvalued at $98?

  • Insmed's Stock Performance: Insmed Inc experienced a significant 45% increase in stock value following positive Phase IIb trial results for its inhalation therapy TPIP, while facing a high valuation at 35x sales and historical volatility during market downturns.

  • Future Outlook and Risks: The company's future success hinges on upcoming FDA decisions and the initiation of Phase 3 trials for TPIP and brensocatib, as continued execution is essential to justify its premium valuation amidst ongoing unprofitability.

Preview
2.0
06-15Benzinga
AppLovin, Chewy And Carvana Are Among Top 11 Large Cap Losers Last Week (June 9-13): Are The Others In Your Portfolio?

  • Stock Performance Overview: Eleven large-cap stocks experienced significant declines last week, with J. M. Smucker Company and Chewy, Inc. leading the losses at 13.67% and 13.57%, respectively, due to disappointing financial results and lowered sales outlooks.

  • Analyst Revisions Impacting Stocks: Several companies, including United Therapeutics Corporation and Lululemon Athletica Inc., faced downward revisions from analysts, contributing to their stock price drops amidst broader market pressures such as rising fuel costs and negative sector sentiment.

Preview
2.0
06-13NASDAQ.COM
United Therapeutics (UTHR) Soars 3.5%: Is Further Upside Left in the Stock?

  • United Therapeutics Stock Performance: United Therapeutics (UTHR) shares increased by 3.5% to $286.14, recovering from a previous decline, influenced by positive results from a pulmonary arterial hypertension study and an upward revision in earnings estimates.

  • Comparison with BioCryst Pharmaceuticals: BioCryst Pharmaceuticals (BCRX) experienced a 2% drop in stock price, maintaining a stable EPS estimate, while it has shown a significant year-over-year growth in earnings expectations.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is United Therapeutics Corp (UTHR) stock price today?

The current price of UTHR is 286.88 USD — it has decreased -0.58 % in the last trading day.

arrow icon

What is United Therapeutics Corp (UTHR)'s business?

United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.

arrow icon

What is the price predicton of UTHR Stock?

Wall Street analysts forecast UTHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UTHR is 370.44 USD with a low forecast of 314.00 USD and a high forecast of 432.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is United Therapeutics Corp (UTHR)'s revenue for the last quarter?

United Therapeutics Corp revenue for the last quarter amounts to 794.40M USD, increased 17.22 % YoY.

arrow icon

What is United Therapeutics Corp (UTHR)'s earnings per share (EPS) for the last quarter?

United Therapeutics Corp. EPS for the last quarter amounts to 6.63 USD, increased 7.46 % YoY.

arrow icon

What changes have occurred in the market's expectations for United Therapeutics Corp (UTHR)'s fundamentals?

The market is revising Upward the revenue expectations for United Therapeutics Corporation (UTHR) for FY2025, with the revenue forecasts being adjusted by 2.08% over the past three months. During the same period, the stock price has changed by -11.17%.
arrow icon

How many employees does United Therapeutics Corp (UTHR). have?

United Therapeutics Corp (UTHR) has 1305 emplpoyees as of June 18 2025.

arrow icon

What is United Therapeutics Corp (UTHR) market cap?

Today UTHR has the market capitalization of 12.94B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free